Search hospitals > Oklahoma > Oklahoma City
University of Oklahoma Health Sciences Center
Claim this profileOklahoma City, Oklahoma 73104
Global Leader in Cancer
Global Leader in Ovarian Cancer
Conducts research for Breast Cancer
Conducts research for Lung Cancer
Conducts research for Pancreatic Cancer
1225 reported clinical trials
90 medical researchers
Summary
University of Oklahoma Health Sciences Center is a medical facility located in Oklahoma City, Oklahoma. This center is recognized for care of Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer and other specialties. University of Oklahoma Health Sciences Center is involved with conducting 1,225 clinical trials across 1,372 conditions. There are 90 research doctors associated with this hospital, such as Rene Y. McNall-Knapp, Debra L. Richardson, Kathleen Moore, M.D., MS, and Raid Aljumaily.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Ovarian Cancer
Global LeaderStage IV
Stage III
BRCA1 positive
Top PIs
Rene Y. McNall-KnappUniversity of Oklahoma Health Sciences Center8 years of reported clinical research
Expert in Cancer
Expert in Brain Tumor
72 reported clinical trials
127 drugs studied
Debra L. RichardsonUniversity of Oklahoma Health Sciences Center3 years of reported clinical research
Expert in Ovarian Cancer
Studies Fallopian Tube Cancer
33 reported clinical trials
52 drugs studied
Kathleen Moore, M.D., MSUniversity of Oklahoma Health Sciences Center1 year of reported clinical research
Expert in Ovarian Cancer
Studies Endometrial Cancer
32 reported clinical trials
83 drugs studied
Raid AljumailyUniversity of Oklahoma Health Sciences Center8 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
26 reported clinical trials
44 drugs studied
Clinical Trials running at University of Oklahoma Health Sciences Center
Lung Cancer
Skin Cancer
Breast Cancer
Breast cancer
Esophageal cancer
Prostate Cancer
Ovarian Cancer
Esophageal Adenocarcinoma
Brain Tumor
Testicular cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Proton Craniospinal Radiation
for Cancer in the Brain and Spinal Cord
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal fluid filled space that surrounds the brain and spinal cord (leptomeningeal metastasis). Patients with leptomeningeal metastasis (LM) may develop multiple areas of nervous system (neurologic) impairment that can be life-threatening. Radiation therapy (RT) effectively relieves local symptoms due to LM. RT uses high energy radiography (x-rays), particles, or radioactive seeds to kill cancer cells and shrink tumors. IFRT is commonly used to treat symptoms of LM. IFRT is radiation treatment that uses x-rays to treat specific areas of LM and to relieve and/or prevent symptoms. pCSI uses protons that can be directed with more accuracy than x-rays which allows treatment of the entire central nervous system space containing the cerebrospinal fluid (CSF), brain, and spinal cord. The pCSI treatment could delay the worsening of LM. Giving pCSI may be better than IFRT in treating LM in patients with breast or non-small cell lung cancer.
Recruiting2 awards Phase 33 criteria
Thoracotomy vs Thoracoscopy
for Metastatic Osteosarcoma
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastases). Open thoracic surgery is a type of surgery done through a single larger incision (like a large cut) that goes between the ribs, opens up the chest, and removes the cancer. Thoracoscopy is a type of chest surgery where the doctor makes several small incisions and uses a small camera to help with removing the cancer. This trial is being done evaluate the two different surgery methods for patients with osteosarcoma that has spread to the lung to find out which is better.
Recruiting2 awards Phase 37 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University of Oklahoma Health Sciences Center?
University of Oklahoma Health Sciences Center is a medical facility located in Oklahoma City, Oklahoma. This center is recognized for care of Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer and other specialties. University of Oklahoma Health Sciences Center is involved with conducting 1,225 clinical trials across 1,372 conditions. There are 90 research doctors associated with this hospital, such as Rene Y. McNall-Knapp, Debra L. Richardson, Kathleen Moore, M.D., MS, and Raid Aljumaily.
Where is University of Oklahoma Health Sciences Center located?
The University of Oklahoma Health Sciences Center hospital is located at 700 NE 13th St, Oklahoma City, OK 73104, at the northwest corner of the intersection of NE 13th St and Lincoln Blvd.
Who should I call to ask about financial aid or insurance network?
The University of Oklahoma Health Sciences Center (OUHSC) provides financial assistance for eligible patients needing emergency or medically necessary care. Patients can apply for this assistance via the OUHSC website and are advised to confirm their insurance coverage by contacting their physician's office directly. For billing inquiries related to OU Health Physicians Tulsa, contact (918) 660-3650 or (918) 619-4400 for assistance in Spanish.
What insurance does University of Oklahoma Health Sciences Center accept?
The University of Oklahoma Health Sciences Center (OUHSC) and OU Health Physicians accept a broad spectrum of insurance plans, including but not limited to Aetna, Blue Cross Blue Shield, Cigna Healthcare, United Healthcare, and MultiPlan/PHCS. Coverage by some plans may vary by location, notably between Oklahoma City and Tulsa. Patients are advised to verify their insurance acceptance with the specific physician's office and consult OU Health hospitals and ERs for comprehensive insurance information.
What awards or recognition has University of Oklahoma Health Sciences Center received?
The University of Oklahoma Health Sciences Center, located in Oklahoma City, Oklahoma, is a premier healthcare research institution, with researchers securing over $140 million in sponsored funding annually since 2017. It houses the Stephenson Cancer Center, the only National Cancer Institute (NCI)-Designated Cancer Center in Oklahoma, offering access to the latest investigational drugs and clinical trials for cancer treatment. Additionally, the Harold Hamm Diabetes Center provides extensive clinical trials and volunteer opportunities for diabetes research.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.